UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other Jurisdiction
of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s
telephone number, including area code: (
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure.
Attached as Exhibit 99.1 to this Current Report is the form of presentation that Blue Water Vaccines Inc. (the “Company”) intends to use in connection with certain meetings and presentations beginning on September 12, 2022 at the H.C. Wainwright Global Investment Conference in New York, New York.
The foregoing (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and will not be deemed to be filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of that section, nor will it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| 99.1 | Corporate Presentation, as of September 2022 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Blue Water Vaccines Inc. | ||
| Date: September 12, 2022 | By: | /s/ Joseph Hernandez |
| Joseph Hernandez | ||
| Chief Executive Officer | ||
2
Exhibit 99.1
September 2022 NASDAQ: BWV
The Presentation (the “Presentation”) has been prepared by Blue Water Vaccines, Inc. (the "Company"). Certain information con tai ned herein has been derived from sources prepared by third parties. While such information is believed to be reliable for the pur pos es used herein, the Company makes no representation or warranty with respect to the accuracy of such information. This Presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities of the Company in any jurisdiction, domestic of foreign, where the offer, solicitation or sale is not permitted or would be unlawful prior to regis tra tion or qualification under the securities laws of any such state or jurisdiction. FORWARD LOOKING STATEMENTS : Certain statements in this presentation (the ”Presentation”) has been prepared by Blue Water Vaccines, Inc . (the “Company”) . This presentation contains forward - looking within the meaning of the Private Securities Litigation Reform Act of 1995 . These statements may be identified by the use of forward - looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others . These forward - looking statements are based on BWV’s current expectations and actual results could differ materially . There are a number of factors that could cause actual events to differ materially from those indicated by such forward - looking statements . These factors include, but are not limited to, risks related to the development of BWV’s vaccine candidates, including, but not limited to BWV - 301 ; the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations ; delays and uncertainties caused by the global COVID - 19 pandemic ; risks related to the timing and progress of clinical development of our product candidates ; our need for additional financing ; uncertainties of patent protection and litigation ; uncertainties of government or third party payor reimbursement ; limited research and development efforts and dependence upon third parties ; and substantial competition . As with any vaccine under development, there are significant risks in the development, regulatory approval and commercialization of new products . BWV does not undertake an obligation to update or revise any forward - looking statement . Investors should read the risk factors set forth in BWV’s Annual Report on Form 10 - K for the fiscal year ended December 31 , 2021 , filed with the Securities and Exchange Commission (the “SEC”) on March 31 , 2022 , Quarterly Report on Form 10 - Q for the quarter ended June 30 , 2022 , filed with the SEC on August 15 , 2022 and periodic reports filed with the SEC on or after the date thereof . All of BWV’s forward - looking statements are expressly qualified by all such risk factors and other cautionary statements . The information set forth herein speaks only as of the date thereof . 2
3 Blue Water Vaccines Overview Broad and Diverse Vaccine Pipeline: Novel preclinical vaccine candidates targeting key infectious diseases, including acute otitis media (middle ear infections), influenza, norovirus, rotavirus, and malaria Accomplished Management Team and Board of Directors: Pipeline development and company success driven by management team and board of directors with extensive and diverse industry experience Esteemed Research Collaborations: Partnerships with renowned researchers, including The University of Oxford, Cincinnati Children’s Hospital Medical Center, & St. Jude Children’s Research Hospital Versatile VLP Vaccine Platform: Novel shell and protrusion (S&P) virus - like particle (VLP) platform with potential to develop multiple vaccine candidates, including influenza, monkeypox, norovirus, and rotavirus Focus on High Unmet Need: Focused development of vaccine candidates targeting high - burden diseases, such as those impacting children and those without efficacious or cost - effective vaccines available Opportunistic Business Model: Exclusive licenses of assets & platforms and targeted business development efforts contribute to an opportunistic business model promoting company growth and expansion
4 Accomplished Management Team and Board of Directors Joseph Hernandez Founder, Chairman & CEO Erin Henderson Chief Business Officer Ronald Cobb, Ph.D. Head of Science and Discovery Jon Garfield Chief Financial Officer Andrew Skibo Head of Biologic Operations Led by experienced entrepreneurs with sustained records of successfully leading innovation and commercialization Board of Directors Michael Venerable Chief Executive Officer , CincyTech Simon Tarsh Retired Senior Managing Director for Deloitte Consulting Kimberly Murphy President & CEO, Oragenics , Inc (NYSE: OGEN) , Clarus (NASDAQ: CRXT) James Sapirstein President & CEO, First Wave Biopharma (NASDAQ: FWBI)
5 Sunetra Gupta, Ph.D. Co - Inventor, Universal Influenza Vaccine (BWV - 101) Dept. of Zoology, University of Oxford Xi Jason Jiang, Ph.D. Co - Inventor, S & P Particle VLP Platform, Norovirus - Rotavirus Vaccine (BWV - 301) Ming Tan, Ph.D. Co - Inventor, S & P Particle VLP Platform, Norovirus - Rotavirus Vaccine (BWV - 301) Assistant Professor, University of Cincinnati, Department of Pediatrics Jason Rosch, Ph.D. Inventor, S. pneumoniae Vaccine (BWV - 201) Associate Member, St. Jude Faculty Renowned Research Partners
6 Blue Water Vaccines Pipeline Infectious Disease Program Candidate Preclinical Phase 1 Phase 2 Phase 3 Collaborator S. pneumo - I nduced Acute Otitis Media BWV - 201 Universal Flu BWV - 101 H1 Pre - Pandemic BWV - 102 Norovirus / Rotavirus BWV - 301 Norovirus / Malaria BWV - 302 BWV is also exploring the applicability of monkeypox within the norovirus VLP platform
VLP Monkeypox Research 7 Blue Water Vaccines Recent Execution Novel S&P Platform Versatility & Expansion of Platform to Show Versatility for Influenza (BWV - 101) Mar Nano Research Publication H3 & Influenza B Epitopes of Limited Variability Discovery for BWV - 101 Apr World Vaccine Congress $8m PIPE: Institutional Investors May St. Jude Platform Expansion Sponsored Research Agreement to Explore Additional AOM - Causing Antigen Expression for BWV - 201 PIPE Financing Butantan Flu Collaboration MoA for Development of BWV - 101 in Brazil Jun SRA to Explore Versatility of S&P VLP Platform CCHMC Platform Research Feb NASDAQ : BWV $20m IPO Initial Public Offering $10m PIPE: Institutional Investors Aug PIPE Financing Research Initiative to Explore Potential for VLP Platform Use in Monkeypox
Our Vaccine Candidates 8
9 BWV - 201: S. Pneumoniae – Induced Acute Otitis Media (AOM) Blue Water Vaccines is committed to alleviating pain in children who suffer from S. pneumoniae induced middle ear infections
10 BWV - 201 Overview Blue Water Vaccines Pipeline • BWV - 201 is a live, attenuated, intranasally delivered, modified strain of 19F Streptococcus pneumoniae • Strain is capable of colonization, but not able to cause invasive disease • Hypothesized to be serotype - independent (e.g., will protect against all AOM - causing strains) • BWV has an exclusive, global license with St. Jude Children’s Research Hospital BWV - 201 Highlights
11 Acute Otitis Media (AOM) Overview • Causes: Infection can be viral, bacterial, or both • Key bacterial pathogens include Streptococcus pneumoniae, non - typeable Haemophilus influenzae, and Moraxella catarrhalis • Key Ages Impacted: Children between 6 – 24mo • ~90% of all children will have at least one episode before school age • Primary Treatment: >80% of AOM cases result in antibiotic prescription in the US 1 • Complications: Infection of mastoid bone 2 , inflammation of the inner ear 2 , and sensorineural hearing loss (SNHL) are all associated with AOM 3 • Insertion of tympanostomy tubes for recurrent AOM is the most common ped. procedure in the US, with approximately 667,000 children <15y undergoing the procedure each year 4 Acute Otitis Media Facts 1) Barbieri, E., Donà , D., Cantarutti , A. et al. Antibiotic prescriptions in acute otitis media and pharyngitis in Italian pediatric outpatients. Ital J Pediatr 45, 103 (2019). https://doi.org/10.1186/s13052 - 019 - 0696 - 9 2) Ren Y, Sethi RKV, Stankovic KM. Acute Otitis Media and Associated Complications in United States Emergency Departments. Otol Neurotol . 2018 Sep;39(8):1005 - 1011. doi : 10.1097/MAO.0000000000001929. PMID: 30113560; PMCID: PMC6097248. 3) Park, J.H., Park, S.J., Kim, Y.H. et al. Sensorineural hearing loss: a complication of acute otitis media in adults. Eur Arch Otorhinolaryngol 271, 1879 – 1884 (2014). https://doi.org/10.1007/s00405 - 013 - 2675 - x 4) Spaw M, Camacho M. Tympanostomy Tube. [Updated 2022 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan - . Available from: https://www.ncbi.nlm.nih.gov/books/NBK565858/
12 Acute Otitis Media Market Opportunity Key Acute Otitis Media Facts & Figures Small percentage of severe complications from AOM 1 2 million emergency department visits 2 5 million US cases of AOM annually 2 More than 10 million antibiotic prescriptions 2 (appx. $4.3B US spent annually on treatment 3 ) Approximately 30 million annual visits for medical care 2 Tympanostomy tube placement, sensorineural hearing loss & mastoid bone inflammation associated with AOM • With more than 80% of all cases resulting in an antibiotic prescription and possibility of reinfection post treatment 4 , antibiotic resistance is of great concern • One study found the majority of S. pneumo strains isolated from children were antibiotic resistant 5 Antibiotic Resistance Current pneumococcal vaccines are serotype - dependent and do not protect against AOM caused by serotypes not included in the vaccine BWV - 201 is serotype - independent and could provide protection against all S. pneumo – induced AOM, as well as AOM caused by other bacterial pathogens 1) Danishyar A, Ashurst JV. Acute Otitis Media. [Updated 2022 Jan 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan - . Available from: https://www.ncbi.nlm.nih.gov/books/NBK470332/ 2) American Academy of Pediatrics and American Academy of Family Physicians, “Questions and Answers on Acute Otitis Media” 3) Tong S, Amand C, Kieffer A, Kyaw MH. Trends in healthcare utilization and costs associated with acute otitis media in the United States dur in g 2008 - 2014. BMC Health Serv Res. 2018 May 2;18(1):318. doi : 10.1186/s12913 - 018 - 3139 - 1. PMID: 29720156; PMCID: PMC5932897. 4) Barbieri, E., Donà , D., Cantarutti , A. et al. Antibiotic prescriptions in acute otitis media and pharyngitis in Italian pediatric outpatients. Ital J Pediatr 45, 103 (2019). https://doi.org/10.1186/s13052 - 019 - 0696 - 9 5) Zielnik - Jurkiewicz B, Bielicka A. Antibiotic resistance of Streptococcus pneumoniae in children with acute otitis media treatment failure. Int J Pediatr Otorhinolaryngol . 2015 Dec;79(12):2129 - 33. doi : 10.1016/j.ijporl.2015.09.030. Epub 2015 Sep 30. PMID: 26454530.
13 BWV - 201 Preclinical Data: Mouse Model 1 NOTE: PCV7 = Prevnar7, PPV23 = Pneumovax23 Incidence of otitis media and sinusitis was significantly lower in BWV - 201 vaccinated mice vs. mock group 1 Other vaccine candidates & PPV23 did not demonstrate significant differences in otitis media or sinusitis vs. mock group 2 BWV - 201 Approach: Mice intranasally vaccinated with BWV - 201 (BHN97ΔftsY) or other live, attenuated vaccines vs. placebo and challenged with BHN97 strain 1) Rosch JW, Iverson AR, Humann J, Mann B, Gao G, Vogel P, Mina M, Murrah KA, Perez AC, Edward Swords W, Tuomanen EI, McCullers JA. A live - attenuated pneumococcal vaccine elicits CD4+ T - cell dependent class switching and provides serotype independent protection against acute otitis media. EMBO Mol Med. 2014 Ja n;6 (1):141 - 54. doi : 10.1002/emmm.201202150. PMID: 24408968; PMCID: PMC3936495.
14 BWV - 201 Preclinical Data: Chinchilla Model 1 Figure A shows BHN97 strain is capable of causing otitis media in chinchillas following intranasal administration Following vaccination, a reduction in the number of culture positive ears in the vaccinated group compared to the mock animals was observed (B) as well as significant reduction in colony forming units (CFUs) from middle ear 7 days post - challenge (C) Approach: Chinchillas intranasally vaccinated with BWV - 201 vs. placebo & challenged with BHN97 S. pneumo strain to understand immunogenicity and efficacy 1) Rosch JW, Iverson AR, Humann J, Mann B, Gao G, Vogel P, Mina M, Murrah KA, Perez AC, Edward Swords W, Tuomanen EI, McCullers JA. A live - attenuated pneumococcal vaccine elicits CD4+ T - cell dependent class switching and provides serotype independent protection against acute otitis media. EMBO Mol Med. 2014 Ja n;6 (1):141 - 54. doi : 10.1002/emmm.201202150. PMID: 24408968; PMCID: PMC3936495.
15 Sponsored Research Agreement Expansion Validation of Optimized Live Attenuated Pneumococcal Vaccines BWV - 201 Platform Hypothesis Research Agreement Development Research Execution & Platform Viability Express antigens from additional AOM - causing pathogens (e.g., non - typeable Haemophilus influenzae & Moraxella catarrhalis) on BWV - 201 surface BWV & St. Jude extended partnership through Sponsored Research Agreement Execute additional expression & test efficacy through animal immunogenicity modeling Sponsored Research Agreement Expansion Signed May 11, 2022 Results Pending, Provisional Patent Filed
16 BWV - 101: Universal Influenza BWV - 102: H1 Pre - Pandemic Aiming to eradicate the flu, universally, with a smart vaccine that targets frequently occurring virulent epitopes
17 BWV - 101 & BWV - 102 Overview Blue Water Vaccines Pipeline • BWV - 101 is a universal influenza candidate with hypothesized protection against H1, H3, and Flu B strains • BWV - 102 is a standalone H1, pre - pandemic, influenza vaccine candidate • Development of both candidates is based on epitopes of limited variability discovered through mathematical modeling at The University of Oxford • BWV holds a global, exclusive license for epitopes of limited variability BWV Influenza Program Highlights
18 Influenza Market Opportunity » 1 billion influenza infections globally and between 290,000 – 650,000 deaths each year 1 » In the US alone, there are about 30 million cases each year and 30,000 – 50,000 related deaths 2 » The total annual economic burden for influenza in the US is about $87 billion 3 » Influenza A and B cause most of human illness and the flu season Influenza Disease Burden × Vaccines need to be manufactured in chicken eggs which increases time and cost × Yearly reformulations rely on predictions as to which strains will be dominant that flu season × Current annual flu vaccine effectiveness ranges from 19% – 50% due to strain variations 4 × Given strain evolution, individuals need to receive shots each year to provide any sort of protection Current Vaccine Shortcomings With 193.8 million flu shots given in the 2020 – 2021 season 5 and an average CDC cost of $14.68 per adult dose 6 , about $2.8 billion was spent on flu shots in the US alone from 2020 - 2021 1) World Health Organization, Global Influenza Programme , “Burden of Disease” 2) Centers for Disease Control and Prevention, “Frequently Asked Questions about Estimated Flu Burden” 3) Molinari NA, Ortega - Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007 Jun 28;25(27):5086 - 96. doi : 10.1016/j.vaccine.2007.03.046. Epub 2007 Apr 20. PMID: 17544181. 4) Centers for Disease Control and Prevention, “CDC Seasonal Flu Vaccine Effectiveness Studies” 5) Centers for Disease Control and Prevention, “Historical Reference of Seasonal Influenza Vaccine Doses Distributed” 6) Centers for Disease Control and Prevention, “CDC Vaccine Price List, July 1, 2022”
19 Epitopes of Limited Variability Overview 1 Our vaccine overcomes such issues by targeting regions, or epitopes, of the virus which are of limited variability. These epitopes remain present through the virus mutations. By identifying multiple epitopes of limited variability, it is possible to produce vaccines or a single vaccine to protect against all previous and future H1 flu strains. Target regions that are highly immunogenic of high variability or evolve frequently. These vaccines need to be updated regularly and administered annually. Current influenza vaccine s can be divided into two groups: Global head domain (variable) Stem / Stalk domain (conserved region) H emagglutinin Target regions that are conserved with low immunogenicity. There is less need for updating these vaccines, but they provide a poor immune response. 1 2 BWV Approach 1) Thompson, C.P., Lourenço , J., Walters, A.A. et al. A naturally protective epitope of limited variability as an influenza vaccine target. Nat Commun 9 , 3859 (2018). https://doi.org/10.1038/s41467 - 018 - 06228 - 8
20 Epitopes of Limited Variability Overview 1 » Oxford Discovery: Antigen/epitope evolution is limited in certain regions of the influenza virus , while previous thought was high evolution within the entire molecule » Epitopes of Limited Variability Immunogenicity: ELVs are naturally immunogenic based on Oxford research o ELVs c ycle between limited number of different conformations and represent optimal vaccine targets » BWV License & Approach: We licensed IP for cross - protective epitopes for our vaccine candidates o Developed at the University of Oxford by Dr. Sunetra Gupta o Mathematical research has pinpointed ELVs that provide immunity to multiple strains o Identified ELVs in historical H1, H3 influenza and I nfluenza B strains to combine into a single, universal influenza vaccine candidate H emagglutinin molecule Oxford mathematical modeling showing certain epitopes (named “OREO”) remain constant over time Epitopes of Limited Variability Discovery & Plan 1) Thompson, C.P., Lourenço , J., Walters, A.A. et al. A naturally protective epitope of limited variability as an influenza vaccine target. Nat Commun 9 , 3859 (2018). https://doi.org/10.1038/s41467 - 018 - 06228 - 8
21 BWV’s Epitopes of Limited Variability Targets One epitope with 7 variants , currently generating additional neutralization data Two epitopes with either 4 or 6 variants, currently generating additional neutralization data One epitope with 5 variants, currently generating additional optimization data between variants Influenza A H1N1 “OREO” Influenza A H3N2 “INDY”, “MAIZ” Influenza B (Yamagata & Victoria Strains) “TATI” BWV - 101 will include selected epitopes from H1, H3, and Influenza B to create a universal influenza vaccine candidate BWV - 102 is a standalone, H1 pe - pandemic influenza vaccine using OREO epitopes Identified Epitopes of Limited Variability
22 Epitopes of Limited Variability Proof of Concept 1 Vaccination of mice with epitopes from H1N1 influenza viruses circulating in 2006 and 1977 provided protection against a strain that last circulated in 1934 Approach: Mice were vaccinated with identified influenza A H1 epitope confirmations and challenged with historical influenza A strains to confirm cross - reactivity and epitope conservation across strains NOTE: Additional figures showing cross - reactivity to other historical strains have been demonstrated 1 BWV - 101 and BWV - 102 contain epitopes of limited variability to provide broad protection against most historic and future influenza strains Mice vaccinated with epitopes confirmations circulating in 2006 or 1977 induced protective immunity to challenge with 1934 strain 1) Thompson, C.P., Lourenço , J., Walters, A.A. et al. A naturally protective epitope of limited variability as an influenza vaccine target. Nat Commun 9 , 3859 (2018). https://doi.org/10.1038/s41467 - 018 - 06228 - 8
23 Epitopes of Limited Variability Proof of Concept 1 Approach: In addition to cross - reactivity, understand if antibodies directed against these epitopes confer protective immunity against historic strains Vaccination with the 2006 - like and 1977 - like OREO epitope confirmations conferred immunity to challenge with a strain that last circulated in 1934 1) Thompson, C.P., Lourenço , J., Walters, A.A. et al. A naturally protective epitope of limited variability as an influenza vaccine target. Nat Commun 9 , 3859 (2018). https://doi.org/10.1038/s41467 - 018 - 06228 - 8
24 S&P Nanoparticle VLP Platform BWV - 301: Norovirus – Rotavirus We aim to create a novel, versatile vaccine platform applicable to multiple infectious diseases for transformative vaccines
25 Versatile Nanoparticle Virus - Like Particle Platform Shell and Protrusion Particle Characteristics x Comprised of 2 nanoparticles: S60 and P24 with norovirus backbone x Ability to present additional antigens on either particle from multiple infectious diseases x Broad therapeutic capabilities and a cost - effective vaccine development platform x Proof - of - concept in animal models showing strong & enhanced immunogenicity
26 BWV - 301 Norovirus - Rotavirus Overview » Norovirus is the most common cause of acute gastroenteritis, with about 700 million cases each year » About 200 million cases are in children under 5 years old, leading to an estimated 50,000 child deaths each year 1 » Estimated $60.3 billion spent on treatment each year 2 » Rotavirus causes an estimated 111 million cases of gastroenteritis each year » 2 million hospitalizations are reported each year, along with 122,000 – 215,000 deaths 3 Norovirus & Rotavirus Impact There are no commercially - available norovirus vaccines despite high disease burden in developed and developing countries While there are several available rotavirus vaccines, efficacy in low - income countries is lower & more efficacious vaccines are needed Vaccination Needs 1) Centers for Disease Control and Prevention, “Norovirus Worldwide” 2) Tan M. Norovirus Vaccines: Current Clinical Development and Challenges. Pathogens. 2021 Dec 19;10(12):1641. doi : 10.3390/pathogens10121641. PMID: 34959596; PMCID: PMC8709042. 3) World Health Organization, “Rotavirus Vaccines: WHO position paper – July 2021”
27 BWV - 301 Preclinical Data: Gnotobiotic Pig Model 1 Approach: Assess the immunogenicity and protective efficacy of the P24 - VP8* nanoparticle in gnotobiotic pig model of human rotavirus infection and disease using mean diarrheal score and quantified viral shedding Vaccinated animals (red) showed significantly reduced duration of diarrhea, lower mean diarrhea scores, and lower cumulative fecal consistency scores Vaccinated animals (red) showed significantly less overall virus shedding compared to unvaccinated (blue), indicating neutralization of the virus NOTE: Red indicates range for vaccinated animals, blue indicates ranges for unvaccinated 1) Ramesh A, Mao J, Lei S, Twitchell E, Shiraz A, Jiang X, Tan M, Yuan AL. Parenterally Administered P24 - VP8* Nanoparticle Vaccine Conferred Strong Protection against Rotavirus Diarrhea and Virus Shedding in Gnotobiotic Pigs. Vaccines (Basel). 2019 Nov 6;7(4):177. doi : 10.3390/vaccines7040177. PMID: 31698824; PMCID: PMC6963946.
28 BWV - 301 Preclinical Data: Gnotobiotic Pig Model 1 P24 - VP8* - specific IgG antibody titers were significantly higher in vaccinated pigs vs. control Approach: Assess the immunogenicity and protective efficacy of the P24 - VP8* nanoparticle in gnotobiotic pig model by measuring antibody titers & immune response indicators NOTE: Red indicates range for vaccinated animals, blue indicates ranges for unvaccinated Serum IgG Levels Serum IgA Levels HRV Neutralizing Antibody Levels Serum IgA titers only detectable after challenge at PCD 7 HRV neutralizing antibodies were detected in serum of vaccinated pigs vs. control pigs only show detection post - challenge HRV = Human Rotavirus 1) Ramesh A, Mao J, Lei S, Twitchell E, Shiraz A, Jiang X, Tan M, Yuan AL. Parenterally Administered P24 - VP8* Nanoparticle Vaccine Conferred Strong Protection against Rotavirus Diarrhea and Virus Shedding in Gnotobiotic Pigs. Vaccines (Basel). 2019 Nov 6;7(4):177. doi : 10.3390/vaccines7040177. PMID: 31698824; PMCID: PMC6963946.
29 BWV - 301 Preclinical Data: Mouse Model Approach: Vaccination of mice with vaccine candidate P 24 particle presenting the small domain of the CS protein (3D7 - PP) and two controls to demonstrate immunogenicity of vaccine candidate Antibody Titer After 2 nd Immunization Antibody Titer After 3 rd Immunization 3D7 - PP 3D7 - His 3D7 - GST 3D7 - PP 3D7 - His 3D7 - GST Mouse 1 25600 800 400 201400 25600 12800 Mouse 2 51200 <100 400 402800 12800 12800 Mouse 3 25600 400 400 201400 25600 12800 Mouse 4 25600 <100 800 402800 12800 12800 Vaccine candidate produces higher titer of antibodies, indicating immune response and potential immunogenicity
30 S&P Nanoparticle VLP Platform BWV - 302: Norovirus – Malaria We aim to create a novel, versatile vaccine platform applicable to multiple infectious diseases for transformative vaccines
31 Malaria Overview » Caused by protozoan parasites from the Plasmodium family » About 219 million cases reported in 2019 leading to an estimated 409,000 deaths globally 1 » Approximately 67% of deaths can be attributed to children 1 » Direct costs of approximately $12 billion worldwide each year 2 Malaria Overview & Impact × One vaccine is available for treatment with limited authorization by the EMA in high transmission regions 3 × Two most common treatments are Chloroquine phosphate & Artemisinin - based combination (ACT) therapies 4 × Growing concern about resistance to mosquito control pesticides and existing malaria treatment 5 Treatment Limitations 1) World Health Organization, “Malaria – Key Facts, 26 July 2022” 2) Centers for Disease Control and Prevention, “Malaria’s Impact Worldwide” 3) World Health Organization, “WHO recommends groundbreaking malaria vaccine for children at risk”, 6 October 2021 4) Mayo Clinic, “Malaria Diagnosis and Treatment” 5) Uwimana , A., Legrand, E., Stokes, B.H. et al. Emergence and clonal expansion of in vitro artemisinin - resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med 26, 1602 – 1608 (2020). https://doi.org/10.1038/s41591 - 020 - 1005 - 2
32 BWV - 302 Overview and Hypothesis IFA of plasmodium sporozoites (3D7) stained with anti - P24 particle presenting the small domain of the CS protein mouse sera The antibodies were also shown to recognize the plasmodium falciparum 3D7 strain using immunofluorescence assays Approach: Incorporate sequences from plasmodium sporozoites into P24 VLP and test VLP viability and test mouse sera for reactivity using immunofluorescence assays 1:1,000 1:2,000 1:8,000 1:16,000 1:32,000 1:4,000 2 nd Ab only, neg - control Plasmodium sporozoites that cause infection can be attached to the P - particle in the S&P platform (detected using immunofluorescence) and may represent a novel malaria vaccine candidate
33 Monkeypox Market & Vaccine Exploration » Monkeypox virus is part of the same family of viruses as variola virus, the virus that causes smallpox 1 » Symptoms are similar to that of smallpox, but milder, and monkeypox is rarely fatal 1 » First human case recorded in 1970, with infrequent cases in several central and western African countries 1 » 2 available monkeypox vaccines: » JYNNEOS vaccine: Live, attenuated, non - replicating smallpox and monkeypox vaccine given in a 2 - dose series with doses 28 days apart 2 » ACAM2000 vaccine: Live vaccinia virus administered via bifurcated needle 2 Monkeypox Overview & Impact BWV Monkeypox Approach x Utilize VLP platform licensed from Cincinnati Children’s to present monkeypox and/or smallpox antigens within the norovirus S & P particles x Once constructs are generated, BWV will assess vaccine’s ability to elicit an immune response in an animal model x Once immunogenicity is assessed, BWV will assess the scalability and manufacturability of the vaccine Monkeypox Vaccine Opportunity x Provide alternative vaccine options to meet global need x Develop non - live vaccines that are still capable of eliciting an immune response 1) CDC, “About Monkeypox”, July 22, 2022 2) CDC, “Monkeypox Vaccines”, August 30, 2022
34 Summary and Recent Milestones Vaccine Candidate DevelopmentsBWV-201: S. pneumoniae - induced AOMo May 2022: Expanded St. Jude Sponsored Research Agreement toexplore presentation of additional AOM-causing pathogens intoBWV-201BWV-101 102: Influenza April 2022: Presented discovery of H3 and Flu B epitopes oflimited variability at World Vaccine Congress May 2022: Announced collaboration with Instituto Butantan fordevelopment of BWV-101 in Brazil May 2022: Expanded Oxford Sponsored Research Agreement tocontinue funding for influenza researchBWV-301 302: VLP S Platformo July 2022: Signed Sponsored Research Agreement with CincinnatiChildren's for VLP Platform Exploration Development August 2022: Announced exploration of VLP platform applicabilityto develop a novel monkeypox vaccine candidate Cash Runway: IPO and subsequent private placements have secured cash runway into 2024
Thank you! Follow us on: https://www.facebook.com/BlueWaterVaccines https://www.linkedin.com/company/blue - water - vaccines - inc/ https://twitter.com/vaccinesInc